{
    "clinical_study": {
        "@rank": "9799", 
        "arm_group": {
            "arm_group_label": "ASP015K and methotrexate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A drug interaction study  to evaluate the effect of ASP015K (twice daily) on the\n      pharmacokinetics (PK) of once weekly oral methotrexate (MTX)."
        }, 
        "brief_title": "A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients check in on day -1 and remain confined until all the exit procedures are performed\n      on the morning of day 10.  Patients to return for 1 post-treatment follow-up visit on day\n      13.\n\n      Patients receive a single dose of methotrexate  on day 1 and day 8 and ASP015K (twice daily)\n      on days 3 through 8 plus the morning of day 9."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. If female, subject must be at least 2 years post menopausal or is surgically sterile\n             per documentation provided by a medical professional and the subject is not pregnant\n             as documented by a negative serum pregnancy test at Screening and negative urine\n             pregnancy test at check-in\n\n          2. If male, subject must agree to sexual abstinence and/or to use a highly effective\n             method of birth control during the study period and for 60 days after the last dose\n             of study drug\n\n          3. Subject must have a clinical diagnosis of Rheumatoid Arthritis (RA) at least 6 months\n             prior to Screening\n\n          4. Subject must be on a stable 15 - 25 mg dose of methotrexate > 28 days prior to\n             Screening\n\n          5. If subject is on a non-biologic disease modifying anti-rheumatic drug (DMARDs)\n             therapy, the dose must be stable > 28 days prior to Screening\n\n          6. Subject must be willing and able to comply with the study requirements\n\n        Exclusion Criteria:\n\n          1. Subject has a previous history of any clinically significant neurological,\n             gastrointestinal, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric,\n             endocrine, hematological disorder or disease, or any other medical condition that\n             would preclude participation in the study\n\n          2. Subject has a known history of positive test for hepatitis B surface antigen (HbsAg)\n             or hepatitis C antibody or history of a positive test for human immunodeficiency\n             virus (HIV) infection\n\n          3. Subject has received live virus vaccination within the last 30 days prior to study\n             drug administration\n\n          4. Subject has a Body Mass Index (BMI) > 35 (kg/m2)\n\n          5. Subject is on biologic disease modifying anti-rheumatic drug (DMARDs) therapy\n\n          6. Subject has a current history of anemia as defined by hemoglobin of less than 12 g/dL\n\n          7. Subject has a recent history (within the last 6 months) of drug or alcohol abuse or a\n             positive urine screen for alcohol or drugs of abuse/illegal drugs at Screening or\n             check-in\n\n          8. Subject has received any investigational agent within 30 days of screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754805", 
            "org_study_id": "015K-CL-PK13"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP015K and methotrexate", 
                "description": "oral", 
                "intervention_name": "ASP015K", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ASP015K and methotrexate", 
                "description": "oral", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ASP015K", 
            "Rheumatoid Arthritis"
        ], 
        "lastchanged_date": "December 19, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Anniston", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "36207"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b, Open-Label, Single Sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development", 
            "last_name": "Central Contact", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of methotrexate (MTX): Area under the concentration-time curve from time of dosing to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 8"
            }, 
            {
                "measure": "Pharmacokinetics of methotrexate (MTX): Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754805"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2010", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}